Hansen Medical and Philips Reinforce Collaboration in Robotic Systems for Endovascular Interventions

Hansen Medical and Philips Reinforce Collaboration in Robotic Systems for 
Endovascular Interventions 
Companies Secure Certified Compatibility of Hansen Medical's
Magellan(TM) Robotic System and Philips' Allura Interventional X-ray
Systems; Magellan System Is Currently the Only Robotic System on the
Market Intended for Use in the Peripheral Vasculature 
MOUNTAIN VIEW, CA, and ANDOVER, MA -- (Marketwired) -- 07/17/13 -- 
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular
robotics, and Royal Philips (NYSE: PHG) (AEX: PHIA) today announced
that they have reached an important milestone in their long-term
collaboration by securing certified compatibility -- article 12 of
the Medical Device Directive 93/42/EEC, as amended by 2007/47/EC --
between Hansen Medical's Magellan(TM) Robotic System and Philips'
Allura interventional X-ray systems. Article 12 compatibility covers
specific technical and service requirements, and means that the
Magellan Robotic System is compatible with Philips' Allura live
image-guidance systems when used according to instructions.  
The Magellan Robotic System uses advanced technology to navigate
peripheral vessels. The Magellan System's proprietary robotic
catheter technology is designed to deliver stability and distal tip
control of a catheter and sheath, as well as robotic control of
standard guidewires. When using the Magellan System, the physician is
seated away from the radiation source and can perform key elements of
the procedure while seated comfortably in a centralized, remote
workstation. 
Philips began collaborating with Hansen Medical on the development of
the Magellan Robotic System in 2010. Hansen Medical subsequently
received CE-marking for the system in 2011 and 510(k) clearance from
the US Food and Drug Administration (FDA) in mid-2012.  
"We are pleased to secure this important certification with Philips,
our longstanding imaging partner for our robotic systems," said Bruce
Barclay, President and CEO of Hansen Medical. "Article 12
compatibility ensures seamless coordination and integration of the
Magellan Robotic System with Philips' most advanced live-image
guidance systems for our hospital and physician customers, enabling
greater access to innovative solutions." 
As a leader in image-guided interventions and therapies, Philips
offers a comprehensive portfolio that includes hybrid operating room
solutions and live-imaging solutions, plus advanced navigation and
interventional tools that work seamlessly with them. The company has
multi-year development programs and collaborations with leading
innovators to improve existing minimally-invasive procedures and
enable new ones. 
"In addition to improving patient outcomes, Philips is committed to
reducing the cost and increasing the speed and safety of image-guided
interventions and therapies through collaboration and meaningful
innovation," said Bert van Meurs, Senior Vice President, General
Manager Integrated Clinical Solutions & Marketing at Imaging Systems,
Philips Healthcare. "We believe that robotic-assisted interventional
techniques have great potential, which is why we have been
collaborating with Hansen Medical for many years now. We continue to
strive for seamless integration of our own and our partners'
innovations to deliver meaningful clinical solutions for our
customers." 
About the Magellan(TM) Robotic System
 Hansen Medical's Magellan
Robotic System is based upon the flexible robotic technology
incorporated in the Sensei-X(R) Robotic Catheter System currently
sold in the U.S. and Europe, which has been used in over 10,000
patients, but includes a number of key enhancements. In particular,
the Magellan Robotic System: 


 
--  Provides solid catheter stability for placement of therapeutic
    devices.
--  Is designed to enable predictable procedure times and increased case
    throughput.
--  Allows for independent, individual robotic control of the distal tips
    of both the outer sheath and the inner leader catheter, as well as
    robotic manipulation of standard guidewires.
--  Is designed to allow for sufficient extension inside the body to
    access hard to reach peripheral anatomy.
--  Preserves the open architecture featured in the Sensei System to allow
    for the subsequent use of many 6F therapeutic devices on the market
    today.
--  Is designed to potentially reduce physician radiation exposure and
    fatigue by employing a remote physician workstation.

  
About Hansen Medical, Inc. 
 Hansen Medical, Inc., based in Mountain
View, California, is the global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System,
NorthStar(TM) Robotic Catheter and related accessories, which are
intended to facilitate navigation to anatomical targets in the
peripheral vasculature and subsequently provide a conduit for manual
placement of therapeutic devices, have undergone both CE marking and
510(k) clearance and are commercially available in the European
Union, and the U.S. In the European Union, the Company's Sensei(R) X
Robotic Catheter System and Artisan Control Catheter are cleared for
use during electrophysiology (EP) procedures, such as guiding
catheters in the treatment of atrial fibrillation (AF), and the
Lynx(R) Robotic Ablation Catheter is cleared for the treatment of AF.
This robotic catheter system is compatible with fluoroscopy,
ultrasound, 3D surface map and patient electrocardiogram data. In the
U.S. the Company's Sensei X Robotic Catheter System and Artisan
Control Catheter were cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in EP procedures. In the United States, the Sensei System
is not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X System and Artisan
Control Catheter for use with cardiac ablation catheters in the
treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
www.hansenmedical.com. 
About Royal Philips: 
 Royal Philips (NYSE: PHG) (AEX: PHIA) is a
diversified health and well-being company, focused on improving
people's lives through meaningful innovation in the areas of
Healthcare, Consumer Lifestyle and Lighting. Headquartered in the
Netherlands, Philips posted 2012 sales of EUR 24.8 billion and
employs approximately 116,000 employees with sales and services in
more than 100 countries. The company is a leader in cardiac care,
acute care and home healthcare, energy efficient lighting solutions
and new lighting applications, as well as male shaving and grooming
and oral healthcare. News from Philips is located at
www.philips.com/newscenter. 
Forward-Looking Statements
 This press release contains
forward-looking statements regarding, among other things, statements
relating to goals, plans, objectives, milestones and future events.
All statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements, including
statements containing the words "plan," "expects," "potential,"
"believes," "goal," "estimate," "anticipates," and similar words.
These statements are based on the current estimates and assumptions
of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances and other
factors that may cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Examples of such statements include statements
about the potential benefits of our Magellan Robotic System for
hospitals, patients and physicians, and the anticipated timing of
commercially launching a 6F vascular catheter. Important factors that
could cause actual results to differ materially from those indicated
by such forward-looking statements include, among others:
engineering, regulatory, manufacturing, sales and customer service
challenges in developing new products and entering new markets; the
commercial viability of our products in the vascular markets;
potential safety and regulatory issues that could slow or suspend our
sales; the effect of economic conditions on capital spending by our
potential customers; the uncertain timelines for the sales cycle for
newly introduced products; the rate of adoption of our systems and
the rate of use of our catheters; the scope and validity of
intellectual property rights applicable to our products; competition
from other companies; our ability to recruit and retain key
personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Quarterly Report on Form 10-Q
for the quarter ended March 31, 2013 filed with the SEC on May 10,
2013 and the risks discussed in our other reports filed with the SEC.
Given these uncertainties, you should not place undue reliance on the
forward-looking statements in this press release. We undertake no
obligation to revise or update information herein to reflect events
or circumstances in the future, even if new information becomes
available.  
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan is a
trademark of Hansen Medical, Inc. in the United States and other
countries. 
For further information, please contact: 
Hansen Medical:
Investor Contacts: 
Peter J. Mariani 
Chief Financial Officer Hansen Medical Inc. 
Tel: +1 650.404.5800  
Brian Ritchie 
FTI Consulting, Inc. 
Tel: +1 212.850.5683 
E-mail: brian.ritchie@fticonsulting.com 
John Capodanno
FTI Consulting, Inc. 
Tel: +1 212.850.5705
E-mail: John.capodanno@fticonsulting.com 
Philips:
Rachel Bloom-Baglin
Philips Healthcare
Tel: +1 978 7609007
E-mail: rachel.bloom-baglin@philips.com 
Steve Klink
Philips Corporate Communications
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com